Sugi Predict

Sugi Predict / Compounds / SCHEMBL9976419

SCHEMBL9976419

SCHEMBL9976419

O=C(NCCCC[C@H](NC(=O)OCc1ccccc1)C(=O)ON1C(=O)CCC1=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 3/20 0.56
▸ TGM2 P21980 3/20 0.53
▸ SIRT2 Q8IXJ6 2/20 0.52
▸ SIRT1 Q96EB6 2/20 0.52
▸ SIRT3 Q9NTG7 1/20 0.52
▸ DPP8 Q6V1X1 1/20 0.52
▸ DPP7 Q9UHL4 1/20 0.52
▸ SIRT5 Q9NXA8 1/20 0.52
▸ KLK7 P49862 1/20 0.51
▸ KLK5 Q9Y337 1/20 0.51
▸ MMP2 P08253 1/20 0.51
▸ MMP9 P14780 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18337922 1.00 FOLH1 (0.56) FOLH1TGM2SIRT2SIRT1SIRT3
SCHEMBL8613001 0.97 FOLH1 (0.52) FOLH1TGM2SIRT2SIRT1SIRT3
SCHEMBL12606016 0.92 KLK7 (0.59) FOLH1TGM2SIRT2SIRT1SIRT3
SCHEMBL29401353 0.92 KLK7 (0.59) FOLH1TGM2SIRT2SIRT1SIRT3
SCHEMBL10983363 0.92 KLK7 (0.59) FOLH1TGM2SIRT2SIRT1SIRT3
SCHEMBL356734 0.92 KLK7 (0.63) FOLH1KLK7KLK5CA1CA2
SCHEMBL2803734 0.92 KLK7 (0.63) FOLH1KLK7KLK5CA1CA2
SCHEMBL16557296 0.89 DPP8 (0.52) FOLH1TGM2DPP8DPP7MMP2
SCHEMBL6859060 0.88 DPP4 (0.54) SIRT2SIRT1SIRT3DPP8DPP7
SCHEMBL29397799 0.88 KLK7 (0.60) FOLH1KLK7KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4171577-B1 PROCESS FOR SYNTHESIZING TARGETING MOLECULES BRISTOL MYERS SQUIBB CO (US) 2026-02-18 — — EP disclosed
EP-4619037-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 — — EP disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
WO-2024105197-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT VINCERX PHARMA GMBH (DE) 2024-05-23 — — WO disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 — — CN disclosed
US-20230250053-A1 PROCESS FOR SYNTHESIZING TARGETING MOLECULES BRISTOL-MYERS SQUIBB COMPANY 2023-08-10 — — US disclosed
US-20230250053-A1 PROCESS FOR SYNTHESIZING TARGETING MOLECULES BRISTOL-MYERS SQUIBB COMPANY 2023-08-10 — — US disclosed
US-20230250053-A1 PROCESS FOR SYNTHESIZING TARGETING MOLECULES BRISTOL-MYERS SQUIBB COMPANY 2023-08-10 — — US disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
WO-2017003721-A1 PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES NORAMCO, INC. (US) 2017-01-05 — — WO disclosed
US-20160376618-A1 PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES NORAMCO, LLC 2016-12-29 — — US disclosed
US-8779191-B2 Methods and compositions for preparing lisdexamfetamine and salts thereof CAMBREX CHARLES CITY, INC. (US) 2014-07-15 — — US disclosed
US-8779191-B2 Methods and compositions for preparing lisdexamfetamine and salts thereof CAMBREX CHARLES CITY, INC. (US) 2014-07-15 — — US disclosed
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2012-07-26 — — US disclosed
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF BLUE OWL CAPITAL CORPORATION, AS NEW AGENT 2012-07-26 — — US disclosed
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof AVISTA PHARMA SOLUTIONS, INC. 2012-06-21 — — US disclosed
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof AVISTA PHARMA SOLUTIONS, INC. 2012-06-21 — — US disclosed
WO-2011050162-A1 PROCESSES FOR PREPARING A POLYMERIC COMPOUND POLYMEDIX, INC. (US) 2011-04-28 — — WO disclosed
WO-2010148305-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF CAMBREX CHARLES CITY, INC. (US) 2010-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190880-A1 METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF PNMT, COMT, DDT FOLH1 512/4885TGM2 2185/4885SIRT2 4087/4885
US-20120157706-A1 Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof SLC6A3, COMT, LPXN FOLH1 679/4885TGM2 3167/4885SIRT2 3835/4885
US-20160376618-A1 PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE AND RELATED DERIVATIVES COMT, MGAM, GAA FOLH1 640/4885TGM2 2779/4885SIRT2 4463/4885
US-20230250053-A1 PROCESS FOR SYNTHESIZING TARGETING MOLECULES RARG, RARA, RARB FOLH1 784/4885TGM2 2786/4885SIRT2 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.